XOMA Royalty to acquire cancer drug developer LAVA Therapeutics

20 hours ago 1

• Healthcare
• M&A

Biotech royalty aggregator XOMA Royalty (NASDAQ:XOMA) has agreed to acquire cancer drug developer LAVA Therapeutics (NASDAQ:LVTX) for $1.16 - $1.24 per share in cash, plus a contingent value right, the companies announced Monday.

As part of the agreement, LAVA (

Recommended For You

More Trending News

See More »

1. Homepage
2. Politics
3. XOMA Royalty to acquire cancer drug developer LAVA Therapeutics